Market Highlights
Porokeratosis is a keratinization issue that is recognized by at least one atrophic macules encompassed by a particular hyperkeratotic, edge like line known as a coronoid lamella.
An assortment of elements, including rising interest for laser treatment, an expansion in renal transfer cases, further developed repayment arrangements in created nations, expanded research financing, and expanded contest among market players, are pushing the worldwide porokeratosis treatment market forward.
Notwithstanding, the significant expense of laser frameworks, an absence of gifted or prepared doctors, drug secondary effects, and an unfortunate medical services framework in low and center pay nations might frustrate market development.
It is assessed that the porokeratosis treatment market is relied upon to enroll a CAGR of 6.0% during the figure time of 2018-2023.
Regional Analysis
The Americas dominates the porokeratosis market owing to the rising prevalence of disseminated superficial actinic porokeratosis and increasing renal transplant cases, as around 10.68% of renal transplant recipients suffered from porokeratosis. According to the National Kidney Foundation, Inc., in 2014, 17,107 kidney transplants took place in the U.S. Moreover, advanced diagnostic and therapeutic solutions, high healthcare expenditure, and the presence of leading players are expected to boost the American porokeratosis treatment market.
Europe holds the second position in the porokeratosis treatment market. It is expected that the rising contribution of various marketers is likely to drive the European porokeratosis treatment market. For instance, in July 2016, Chugai and Galderma announced the global license agreement for the development and marketing of Nemolizumab worldwide. The Nemolizumab is a novel biologic for skin diseases.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/6067
Asia Pacific is the quickest developing porokeratosis treatment market inferable from a gigantic patient pool, expanding interest for medicines, and rising medical care consumption. Around here, the Mibelli type is generally regular when contrasted with different sorts. In Singapore, the Mibelli kind of porokeratosis was available in 56% of porokeratosis patients in 2013, proposed by a review distributed in the Cases in Dermatology.
The Middle East and Africa holds the least portion of the worldwide porokeratosis treatment market because of the presence of poor and slow agricultural nations, particularly, in the African area.
Segmentation
The global porokeratosis treatment market is segmented on the basis of type of porokeratosis, diagnosis and treatment, and end-user.
On the basis of type of porokeratosis, the market is classified as Disseminated Actinic Porokeratosis (DSAP), linear porokeratosis, porokeratosis of mantoux, Porokeratotic Eccrine Ostial And Dermal Duct Nevus (PEODDN), and punctate porokeratosis.
Based on diagnosis and treatment, the market is classified as diagnosis and treatment. The diagnosis segment is further classified as biopsy, differential diagnosis, and others. The sub-segments of differential diagnosis include squamous cell carcinoma, lichenoid keratosis, and epidermal nevus. The treatment segment is further classified as topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-Fluorouracil, immunomodulators, photodynamic therapy, retinoids, cryotherapy, lasers, immunosuppressive agents, and others. The sub-segments of immunomodulators include imiquimod and resiquimod. The sub-segments of retinoids include topical retinoids and oral retinoids. The sub-segments of immunosuppressive agents include calcineurin inhibitors and others.
By end-user, the market is classified as hospitals and clinics, diagnostic centers, drug stores, research and academic institutes, and others.
Key Players
Some of the key players in the global porokeratosis treatment market are Angiodynamics, Inc. (U.S.), Allergan (Republic of Ireland), Alma Lasers (Israel), Beiersdorf AG (Germany), Biogen (U.S.), Biolase Inc. (U.S.), Coherent, Inc. (U.S.), Coty Inc. (U.S.), Cutera (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (U.S.), IPG Photonics Corporation (U.S.), IRIDEX Corp. (U.S.), L’Oreal (France), Lumenis (U.S.), Pfizer (U.S.), PhotoMedex, Inc. (U.S.), Valeant Pharmaceuticals (Canada), and others.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/porokeratosis-market-6067
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
